Russian Heart Failure Journal 2006year Effects of the angiotensin antagonist irbesartan, the angiotensin converting enzyme inhibitor enalapril, and their combination on clinical signs, hemodynamics and cardiac morpho-functional parameters in patients with chronic heart failure


To access this material please log in or register

Register Authorize
2006/

Effects of the angiotensin antagonist irbesartan, the angiotensin converting enzyme inhibitor enalapril, and their combination on clinical signs, hemodynamics and cardiac morpho-functional parameters in patients with chronic heart failure

Lapidus N.I., Sizova Zh.M.

Keywords:

DOI:

Urgency: Role of AII receptor antagonists in the treatment of CHF is one of the most important and interesting problems. Results of several large-scale studies using these drugs has appeared contradictory. In this connection we conducted a study with the aim of comparing effects of the angiotensin antagonist irbesartan, the ACEI enelapril and a combination thereof on clinical signs, hemodynamics, cardiac morpho-functional parameters and exercise tolerance in patients with IHD complicated with CHF. Materials and methods: Time course of CHF clinical signs, cardiac morpho-functional parameters (EDC, EDR, EF) and exercise tolerance by bicycle ergometry were assessed during therapies with irbesartan, enalapril and their combination as a part of conventional therapy in 99 patients with II–IV FC CHF and LV EF≤45%). Results: After 24 weeks of continuous treatment, efficacy of irbesartan, enalapril and their combination was comparable and evident as decreases in CHF FC by 16.3; 16.6 and 16.4%, respectively; increases in LV EF by 4.9, 6.9 and 6,7%, respectively; increases in exercise tolerance and duration. Conclusion: Irbesartan, enalapril and their combination showed comparable clinical efficacy but irbesartan had the best tolerability.

To access this material please log in or register

Register Authorize
Ru En